With the holidays in full swing already, Cramer thought this would be a good time to focus on the best ways for investors to play the holidays in their portfolio. And, for anyone who has young children, that could involve a toy made by Mattel or Hasbro.
Maybe even both, for those who want to keep their kid in a good mood.
For the past few years, if anyone asked Cramer how to play the toy space, he would have said to buy Hasbro. It has the best licensing deals and movie associations, including many partnerships with Disney. Mattel was known as a much more old-school play, selling things like Barbie, Fisher Price toys and Matchbox cars.
But, lately, it seems that the two toy stocks have reversed trajectories dramatically, with Mattel roaring higher and Hasbro falling dramatically.
So can the trend continue?
To find out, Cramer turned to Tim Collins, a technician and colleague of Cramer's at RealMoney.com. When Collins consulted the charts for the future of these two toy companies, he discovered that the new pattern is poised to continue with Mattel leading the way.
Read More Cramer: The winner of holiday toy shopping is...
Another company that has a lot going for it is Seres Therapeutics, a small, development-stage biotech that skyrocketed when it game public in June and has since been very volatile.
Seres is all about creating a new class of medicines that treat diseases caused by dysbiosis — when the bacterial ecosystem that lives in your digestive tract becomes unbalanced, causing individuals to become very sick.
The company's lead drug is a pull that prevents recurrent CDO, an inflammation of the large intestine that is the leading cause of hospital acquired infections in the U.S. On Monday, investors learned that Seres' approach to treating diseases could have many more potential indications, including ulcerative colitis.
To learn more, Cramer spoke with the company's chairman and CEO, Dr. Roger Pomerantz. The CEO explained that many of the treatments currently available for conditions such as ulcerative colitis create suppression to the immune system, which could lead to infections or tumors.
"We have a drug, SER-287, that is in clinical trials that we announced yesterday in ulcerative colitis, which we expect to be totally non-immunosuppressant," Dr. Pomerantz said.
In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:
Wynn Resorts, Limited: "I love Steve Wynn [CEO] I love what he has built, but MGM has got that balance between Macau and Vegas that I need. So MGM is the play."
Nucor Corporation: "If I had to recommend a steel company it would be Nucor, it yields 3.73, but I'm not going to because the metals and mining remain a very weak place. Look at KMT and what happened when they preannounced. It was down almost $5 today on a $25 basis."
Read MoreLightning Round: I'm worried this group is peaking